| Aracely I Chavez, | |
|
719 N Marion St, Oak Park, IL 60302-1530 | |
| (844) 478-6878 | |
| Not Available |
| Full Name | Aracely I Chavez |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 719 N Marion St, Oak Park, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255021317 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Aracely I Chavez, 4848 W Wrightwood Ave Apt D2, Chicago, IL 60639-1744 Ph: (773) 991-2826 | Aracely I Chavez, 719 N Marion St, Oak Park, IL 60302-1530 Ph: (844) 478-6878 |
News Archive
For the second time in a month, a federal judge has temporarily halted a law aimed at abortion clinics. U.S. District Judge J. Thomas Marten issued a preliminary injunction Monday that blocks Kansas from stripping federal family-planning funds from Planned Parenthood. He ordered the state to start distributing the money to the agency.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company's two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time.
A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.
› Verified 7 days ago
Kelly Boris, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 719 N Marion St, Oak Park, IL 60302 Phone: 312-401-0975 | |
Mrs. Anne Elizabeth Ciosek, M.A.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 260 Madison St, Oak Park, IL 60302 Phone: 708-524-3110 | |
Madeline S Kubiak, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 429 N Marion St Ste 203, Oak Park, IL 60302 Phone: 312-945-8305 | |
Abbey Blender, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 135 N Harvey Ave, Oak Park, IL 60302 Phone: 917-620-7916 | |
Ms. Julie Cameron, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 411 Chicago Ave, Oak Park, IL 60302 Phone: 708-524-1050 Fax: 708-524-2469 | |
Ics Rehab Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1104 N Taylor Ave, Oak Park, IL 60302 Phone: 708-519-0786 Fax: 708-386-4351 | |
Ms. Susan Jill Kupperman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 411 Chicago Ave, Oak Park, IL 60302 Phone: 708-524-1050 |